



Dermatology



S. Karger
Medical and Scientific Publishers
Basel · Freiburg · Paris
London · New York · Chennai ·
New Delhi · Bangkok · Beijing ·
Shanghai · Tokyo · Kuala Lumpur ·
Singapore · Sydney

KARGER



Dermal Fillers

Editor
David J. Goldberg

Dermal Fillers

Editor: Goldberg, D.J. (New York, NY)
VI + 144 p., 66 fig., 62 in color, 7 tab., 2018
CHF 112.00 / EUR 105.00 / USD 132.00
Hard cover or online prices for personal customers
Prices subject to change, VAT not included
EUR price for eurozone countries,
USD price for USA and Latin America only
ISBN 978-3-318-06124-6
e-ISBN 978-3-318-06125-3

Aesthetic Dermatology, Vol. 1-4
Series Editor: Goldberg, D.J. (New York, NY)
ISSN 2235-8609 / e-ISSN 2235-8595

Listed in MEDLINE/PubMed



The aging process affects every aspect of the body, with the face being one of the first places to show signs. The search for the perfect injectable filler has taken an interesting path with the majority of innovations having been introduced in the last 30 years. The patient-driven demand for safe and effective minimally invasive aesthetic procedures has led to the development of an expanding and competitive market for dermal fillers. The demand for soft tissue augmentation has grown rapidly since its start in 1981 with collagen fillers. Fillers using hyaluronic acid, calcium hydroxyapatite, poly-L-lactic acid, and polymethylmethacrylate provide a wide range of options so that the best cosmetic outcome can be attained. The ability to correct facial rhytides and folds, to augment lips and cheeks, to correct acne scars, and now even to replenish volume loss in the dorsum of the hands is something that many practitioners thought would never be possible. This publication reviews the history of fillers, injection techniques, complications and safety as well as the novel use of fillers and fillers of the future.

Contents

- Preface: **Goldberg, D.J.**
- History of Fillers: **Narins, R.S.; Mariwalla, K.**
- Anatomy for Facial Fillers: The Skin Surface and Beyond: **Sykes, J.; Allak, A.; Palhazi, P.; Cotofana, S.**
- Neocollagenesis: **Handler, M.Z.; Goldberg, D.J.**
- Hyaluronic Acid in Dermal Fillers: **Goldie, K.; Voropai, D.**
- Calcium Hydroxylapatite (Radiesse): **Friedman, D.P.**
- Safe and Effective Injection Technique: **Funt, D.K.**
- Novel Use of Fillers (Chin, Nose, Hands): **Marmur, E.**
- Soft Tissue Augmentation in the US: **Nestor, M.S.; Bass, A.M.; Gold, M.H.**
- Complications of Cosmetic Fillers: **Grunebaum, L.D.; Funt, D.K.**

Author Index / Subject Index

Dear Librarian

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger representative.

The easiest way to order: www.karger.com/aed

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

KARGER

Dermatology

An International Journal founded as

“Dermatologische Zeitschrift” by Oskar Lassar (1893–1907)

Continued by Erich Hoffmann (1908–1938), continued as “Dermatologica” (1939–1991),
by Wilhelm Lutz (1939–1958), Rudolf Schuppli (1959–1985) and J.-H. Saurat (1986–2015),
continued as “Dermatology” since 1992

Editor-in-Chief

Gregor B.E. Jemec – *Zealand University Hospital, Roskilde, Denmark*

Section Editor “Atopic Dermatitis and Genetics”

Tove Agner – *Bispebjerg University Hospital, Copenhagen, Denmark*

Section Editor “Dermoscopy and Imaging”

Giuseppe Argenziano – *University of Campania, Naples, Italy*

Section Editor “International Dermatology Outcome Measures”

Amit Garg – *Hofstra Northwell School of Medicine, Hempstead, USA*

Section Editor “Skin Cancer”

Ketty Peris – *Catholic University, Rome, Italy*

Section Editor “Tattoo and Body Art”

Jørgen Serup – *Bispebjerg University Hospital, Copenhagen, Denmark*

Associate Editors

Perla Calderón – *University of Chile, Santiago, Chile*

Lars E. French – *University Hospital Zurich, Zurich, Switzerland*

Robert Gniadecki – *Bispebjerg University Hospital, Copenhagen, Denmark*

Qiang Ju – *Renji Hospital, Shanghai Jiao Tong University, Shanghai, China*

Brian Kirby – *St. Vincent’s University Hospital, Dublin, Ireland*

Dan Lipsker – *University of Strasbourg, Strasbourg, France*

Branka Marinović – *University Hospital Center Zagreb, Zagreb, Croatia*

(Continued on next page)

Official Organ of

Swiss Society for Dermatology and Venereology

Schweizerische Gesellschaft für
Dermatologie und Venerologie
Société Suisse de
Dermatologie et Vénérologie



Japanese Society for
Dermatoallergy and
Contact Dermatitis



European Society of Tattoo and Pigment Research

Tetsuo Shiohara – *Kyorin University*, Tokyo, Japan
H. Peter Soyer – *The University of Queensland*, Woolloongabba, Australia
Dae Hun Suh – *Seoul National University*, Seoul, Republic of Korea
Jacek C. Szepietowski – *University of Wroclaw*, Wroclaw, Poland
Christos C. Zouboulis – *Dessau City Clinic*, Dessau, Germany

Editorial Board

Hervé Bachelez – *St. Louis Hospital*, Paris, France
Tania Cestari – *Federal University of Rio Grande do Sul*, Porto Alegre, Brazil
Veronique del Marmol – *Université Libre de Bruxelles*, Brussels, Belgium
Lennart Emtestam – *Karolinska University Hospital and Institutet*,
Stockholm, Sweden
Alice Gottlieb – *New York Medical College*, Valhalla, USA
Dimitrios Ioannides – *Aristotle University Medical School*, Thessaloniki,
Greece
Marcel F. Jonkman – *University Medical Center Groningen*, Groningen,
The Netherlands
Jürgen Lademann – *Charité – Universitätsmedizin Berlin*, Berlin, Germany
Sirkkku Peltonen – *University of Turku and Turku University Hospital*, Turku,
Finland
Errol P. Prens – *Erasmus Medical Center*, Rotterdam, Netherlands
Luis Puig – *Autonomous University of Barcelona*, Barcelona, Spain
Jean Revuz – *Private Practice – Dermatology*, Paris, France
Eggert Stockfleth – *Ruhr University Bochum*, Bochum, Germany
Devinder Mohan Thappa – *Jawaharlal Institute of Postgraduate Medical
Education and Research*, Puducherry, India

Submission

Only original papers written in English should be sent to:

www.karger.com/drm

S. Karger AG
Prof. Dr. Gregor B.E. Jemec
Editorial Office "Dermatology"
PO Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1358
Fax +41 61 306 1434
E-Mail drm@karger.com

Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publisher. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of *Dermatology* and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Peer Review Policy

Dermatology is a peer-reviewed journal. Our aim is to provide authors with fast and constructive feedback regarding their submitted manuscript. The Editor-in-Chief and international editorial board ensure a thorough and fair peer review and the highest scientific publishing standards. The Editor-in-Chief is responsible for maintaining a high-quality peer review of papers submitted to the journal.

Types of Papers

The journal accepts the following types of papers:

- Original Papers
- Review Papers
- Industry News
- Basic Science Investigations
- Clinical Investigations
- Novel Treatments
- Surgical Pearls
- Consensus Guidelines

Original Papers: Fully documented reports of original research. They must describe full sets of significant, original experiments in basic science and translational research in dermatology. Consideration for publication is based on originality, novelty, scientific soundness and appropriate analysis. An Abstract, Introduction, Materials and Methods, Results and Discussion sections are required. The abstract should be structured and contain the following parts: Background, Objective, Methods, Results, Conclusion; it should have no more than 250 words. A synopsis of the Material and Methods section must be provided in a flow chart. The detailed paragraph will be published as supplementary material. The submission of raw data as supplementary material is strongly encouraged.

Review Papers: Comprehensive reviews covering a timely topic by experts in the field.

Review Papers are usually invited by the Editor but may be unsolicited. An abstract (not structured) of no more than 250 words is required. Review Papers are not subject to page charges, and color illustrations are reproduced free of charge in the printed edition. All published Review Papers are freely accessible online.

Surgical Pearls: Presentation of novel surgical techniques and discussion of their advantages compared to current approaches. Papers of this type should include a short video sequence to be published online.

Consensus Guidelines: Consensus guidelines are welcome from societies or working groups to provide guidance in key and emerging areas in all fields of dermatology.

Sections

International Dermatology Outcome Measures: The section includes papers, the research focus of which is in alignment with the mission of the non-profit organization "International Dermatology Outcome Measures" (IDEOM): The development of evidence-based outcomes measures to evaluate the impact of treatments for patients with dermatological diseases. Please view the above "Types of Papers" list for all different paper categories accepted within this section. All submissions to this section are subject to editorial and peer-review. *Dermatology* publication conditions apply.

Skin Cancer: The section with a thematic focus on Skin Cancer includes papers on any cancers that arise from the skin (basal-cell cancer (BCC), squamous-cell cancer (SCC) and melanoma). Please view the above "Types of Papers" list for all different paper categories accepted within this section. All submissions to this section are subject to editorial and peer-review. *Dermatology* publication conditions apply.

Tattoo and Body Art: *Dermatology* welcomes submissions to the section "Tattoo and Body Art" covering various types of body art and skin modifications (namely tattooing, permanent make-up, body-piercing, scarification, etc.) and including basic research and science on those topics. Please view the above "Types of Papers" list for all paper categories accepted within this section. All submissions to this section are subject to editorial and peer-review. *Dermatology* publication conditions apply.

Ethics

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research, and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor.

Arrangement

Papers should comprise approximately 9 double-spaced manuscript pages including figures, tables and references. For technical details please refer to: www.karger.com/electronic_submission.

Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: For indexing purposes, a list of 3–10 key words in English is essential for all papers.

Key message: Kindly provide a sentence of up to 15 words that capture the essence of the content of the paper.

Material and Methods: A synopsis of the Material and Methods section must be provided in a flow chart. The detailed paragraph will be published as supplementary material.

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be stored in separate files. Tables require a heading and figures a legend, also prepared in a separate file. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. For further details, please refer to the Submission Website at www.karger.com/drm.

Color illustrations: All color illustrations will be published in color online and black/white in print. In print, optional publication of illustrations in color is subject to a charge of CHF 960.00 per page.

Dermatology

No charges are imposed for color illustrations of Review Papers.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Avoid using abstracts and posters as references. If necessary, list as footnotes in standard reference format, followed by the designation "(abstr.)" or "(poster)". For posters, add the details of the meeting where presented.

Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(a) *Papers published in periodicals:* Chatel JM, Bernard H, Orson FM: Isolation and characterization of two complete Ara h 2 isoforms cDNA. *Int Arch Allergy Immunol* 2003;131:14–18.

(b) *Papers published only with DOI numbers:* Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. *Int Arch Allergy Immunol* DOI: 10.1159/000063858.

(c) *Monographs:* Matthews DE, Farewell VT: *Using and Understanding Medical Statistics*, ed 3, revised. Basel, Karger, 1996.

(d) *Edited books:* DuBois RN: Cyclooxygenase-2 and colorectal cancer; in Dannenberg AJ, Dubois RN (eds): *COX-2*. *Prog Exp Tum Res*. Basel, Karger, 2003, vol 37, pp 124–137.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modifica-

tion or editing. Files should not exceed 10 Mb in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at <https://karger.figshare.com> under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:

"This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. *Cytogenet Genome Res* 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at [http://www.karger.com/?doi=\[insert DOI number\]](http://www.karger.com/?doi=[insert DOI number])."

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author's behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's Choice™ (Gold Open Access) articles, see Author's Choice™.

Author's Choice™

Karger's Author's Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice. The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:

"The final, published version of this article is available at [http://www.karger.com/?doi=\[insert DOI number\]](http://www.karger.com/?doi=[insert DOI number])."

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders' requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approximately 9 double-spaced manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.

E-Pub First

All articles are published electronically ahead of print with a DOI number and are supplemented later with the definite reference of the printed version. The articles become available immediately after the authors' approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.

Reprints

Order forms are sent with the proofs. Orders submitted after the issue has been printed are subject to considerably higher prices.

Dermatology

General Information

ISSN Print Edition: 1018-8665
ISSN Online Edition: 1421-9832

Journal Homepage: www.karger.com/drm

Publication Data: *Dermatology* is published 6 times a year. Volume 233 with 6 issues appears in 2017.

Copyright: © 2017 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

Personal subscription:

Print or Online	Print+Online combined
CHF 1642.00	CHF 1692.00
EUR 1480.00	EUR 1520.00
USD 1785.00	USD 1839.00

postage and handling (added to print and print+online)
CHF 48.00 Europe, CHF 69.60 Overseas
EUR 43.20
USD 67.20

Institutional subscription:

Print or Online	Print+Online combined
CHF 3284.00	CHF 3777.00
EUR 2959.00	EUR 3403.00
USD 3570.00	USD 4106.00

postage and handling (added to print and print+online)
CHF 60.00 Europe, CHF 87.00 Overseas
EUR 54.00
USD 84.00

Discount subscription prices:

For members of Dermatology Societies.

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including *Current Contents*® and PubMed/MEDLINE.

Subscription Orders:

Orders can be placed at any bookstore, subscription agency, directly with Karger Publishers, or with one of our representatives:

S. Karger AG

Medical and Scientific Publishers
P.O. Box
4009 Basel
Switzerland
t: +41 61 306 11 11
f: +41 61 306 12 34
e: karger@karger.com
w: www.karger.com

(for courier services only:
Allschwilerstrasse 10
4055 Basel/Switzerland)

Germany

S. Karger GmbH
Postfach
79095 Freiburg
Deutschland
(Hausadresse: Wilhelmstrasse 20A,
79098 Freiburg)
t: +49 761 45 20 70
f: +49 761 45 20 714
e: information@karger.com
w: www.karger.de

Japan

Karger Japan, Inc.
Shiba Daimon Asahi Bldg. 2F
1-2-23 Shiba Daimon
Minato-ku
Tokyo 105-0012
Japan
t: +81 3 6435 6242
f: +81 3 6435 6244
e: publisher@karger.jp
w: www.karger.jp

USA

S. Karger Publishers, Inc.
26 West Avon Road
P.O. Box 529
Unionville, CT 06085
USA
Toll free: +1 800 828 5479
t: +1 860 675 7834
f: +1 860 675 7302
e: kargerusa@karger.com

France

Enter & Read
Albertine Luginbuhl
23, rue du Départ, boîte 37
75014 Paris
France
t: +33 6 81 04 76 85
e: albertineluginbuhl@orange.fr

South East Asia, China and Taiwan

Karger Regional Office (Malaysia)
Level 28-03-03A, PJ Exchange
No. 16A, Persiaran Barat
46050 Petaling Jaya
Selangor Darul Ehsan
Malaysia
t: +60 3 7962 0158
f: +60 3 7962 0001
e: service@karger.cn; r.chew@karger.cn

Karger China

51F Raffles City Centre
268 Xi Zang Middle Road
Huang Pu District
Shanghai 200001
P.R. China
t: +86 21 2312 7673
f: +86 21 2312 7777
e: service@karger.cn
r.chew@karger.cn
w: www.karger.cn

India, Bangladesh, Sri Lanka

Karger India
G202 Jaipuria Sunrise Green
Indrapuram
Ghaziabad 201014
Uttar Pradesh
India
t: +91 98 10958 282
e: s.chanda@kargerindia.com

Change of Address:

Both old and new address should be sent to the subscription source.


KARGER

© 2017 S. Karger AG, Basel

E-Mail karger@karger.com
www.karger.com

The Journal Home Page is available at:
www.karger.com/drm

A clinical guide for all practitioners



Itch – Management in Clinical Practice

Editors
Jacek C. Szepietowski
Elke Weisshaar



Itch – Management in Clinical Practice

Editors: Szepietowski, J. C. (Wroclaw); Weisshaar, E. (Heidelberg)
VIII + 210 p., 28 fig., 26 in color, 36 tab., 2016
CHF 189.00 / EUR 177.00 / USD 222.00
Hard cover or online prices for personal customers
Prices subject to change, VAT not included
EUR price for eurozone countries,
USD price for USA and Latin America only
ISBN 978-3-318-05888-8
e-ISBN 978-3-318-05889-5

Current Problems in Dermatology, Vol. 50

Series Editor: Itin, P. (Basel); Jemec, G.B.E. (Roskilde)

Listed in MEDLINE/Pubmed, Thomson Reuters indices



Albeit a very common symptom in dermatology, internal medicine, psychosomatics, neurology, and even oncology, itching was under-researched up until 15 years ago. Since then, the clinical aspects of acute and chronic itch have been examined extensively. As a result, some books on the topic have become available. Whereas most publications focus on experimental aspects and diagnostics, this volume of the series 'Current Problems in Dermatology' provides a comprehensive overview regarding the management of chronic itch. Select authors consider interdisciplinary aspects as well as age, body region, and specific diseases as they present a great variety of available treatments. All physicians with patients suffering from itch – especially dermatologists, general practitioners, gerontologists, nephrologists, hepatologists, neurologists, and palliative care doctors – will find this publication to be an essential source of information.

Contents

Preface: **Szepietowski, J.C.; Weisshaar, E.**

- Classification of Itch: **Ständer, S.**
- Epidemiology of Itch: **Weisshaar, E.**
- Central Mechanisms of Itch: **Carstens, E.; Akiyama, T.**
- Peripheral Mechanisms of Itch: **Azimi, E.; Xia, J.; Lerner, E.A.**
- Diagnostic Procedures of Itch: **Reich, A.; Szepietowski, J.C.**
- Measurement of Itch Intensity: **Reich, A.; Szepietowski, J.C.**
- Itch Management: General Principles: **Misery, L.**
- Itch Management: Topical Agents: **Metz, M.; Staubach, P.**
- Itch Management: Systemic Agents: **Pongcharoen, P.; Fleischer Jr., A.B.**
- Itch Management: Physical Approaches (UV Phototherapy, Acupuncture): **Chan, I.H.Y.; Murrell, D.F.**
- Itch Management: Psychotherapeutic Approach: **Evers, A.W.M.; Schut, C.; Gieler, U.; Spillekom-van Koulik, S.; van Beugen, S.**
- Itch Management: Treatments under Development: **Pereira, M.P.; Ständer, S.**
- Itch in Urticaria Management: **Deza, G.; Gimenez-Arnau, A.M.**
- Itch in Atopic Dermatitis Management: **Kamata, Y.; Tominaga, M.; Takamori, K.**
- Prurigo Nodularis Management: **Tsianakas, A.; Zeidler, C.; Ständer, S.**
- Itch in Psoriasis Management: **Szepietowski, J.C.; Reich, A.**
- Itch in Special Skin Locations Management: **Misery, L.**
- Neurologic Itch Management: **Šavk, E.**
- Psychogenic Itch Management: **Szepietowski, J.C.; Reszke, R.**
- Uremic Itch Management: **Mettang, T.**
- Cholestatic Itch Management: **Mittal, A.**
- Paraneoplastic Itch Management: **Rowe, B.; Yosipovitch, G.**
- Drug-Induced Itch Management: **Ebata, T.**
- Itch in Pregnancy Management: **Lambert, L.**
- Itch Management in Childhood: **Fölster-Holst, R.**
- Itch Management in the Elderly: **Leslie, T.A.**

Author Index/Subject Index

Dear Librarian

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

The easiest way to order: www.karger.com/cupde

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

KARGER

Contents

[See the journal website for contents](#)

AMWC

16th Aesthetic & Anti-aging
Medicine World Congress

▶ 5, 6 & 7

APRIL 2018

GRIMALDI FORUM
MONACO



Under the High Patronage
of H.S.H. Prince Albert II of Monaco

www.euromedicom.com

informa
exhibitions





EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY

European Academy of Allergy
and Clinical Immunology
26 – 30 May 2018
Munich, Germany



EAACI Congress 2018

**Innovative Solutions
for Allergy**



www.eaaci.org

#eaaci2018

The first e-learning platform dedicated to dermatology, plastic surgery and aesthetic science

BE PART OF THE FASTEST GROWING COMMUNITY
MORE THAN 12,500 PHYSICIANS

IMCAS Academy


Subscribe now online

ACADEMY.IMCAS.COM

MORE THAN
2,000
VIDEOS

ONLY
390 USD
FOR 12-MONTH
FULL ACCESS
SUBSCRIPTION

FOLLOW US
IMCASACADEMY



MARK YOUR CALENDAR




COLOMBIA

IMCAS AMERICAS
CARTAGENA – MARCH 15 TO 17, 2018



SOUTH KOREA

IMCAS ASIA
SEOUL – JULY 27 TO 29, 2018



FRANCE

IMCAS ANNUAL
WORLD CONGRESS
PARIS – JAN 31 TO FEB 2, 2019

F18124



PARIS (FRANCE): +33 1 40 73 82 82 | HONG-KONG: +852 6054 3312




CONTACT@IMCAS.COM

FOLLOW US



A valuable tool for clinical practice



Diagnosis and Therapy of Tattoo Complications

With Atlas of Illustrative Cases

Editors
Jørgen Serup
Wolfgang Bäumlér

Diagnosis and Therapy of Tattoo Complications

With Atlas of Illustrative Cases
Editors: Serup, J. (Copenhagen);
Bäumlér, W. (Regensburg)
VIII + 234 p., 242 fig., 239 in color, 8 tab., 2017
CHF 168.00 / EUR 157.00 / USD 198.00
Hard cover or online prices for
personal customers
Prices subject to change, VAT not included
EUR price for eurozone countries,
USD price for USA and Latin America only
ISBN 978-3-318-05977-9
e-ISBN 978-3-318-05978-6

Current Problems in Dermatology, Vol. 52
Series Editor: Itin, P. (Basel);
Jemec, G.B.E. (Roskilde)
ISSN 1421-5721 / e-ISSN 1662-2944

Listed in MEDLINE/Pubmed,
Thomson Reuters indices



Dear Librarian

I have reviewed this publication and
would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop,
subscription agency, directly with the publisher
or through a Karger representative.

Tattooing breaches the skin and can, therefore, cause a variety of complications. This book covers the full spectrum of issues clinical practitioners may encounter when treating affected patients. Introductory chapters include educational information on methods for tattooing, types of tattoos, tattoo inks, and tattoo ink toxicology. The focus is on the diagnosis and classification of tattoo complications. In this regard, a comprehensive atlas of acute and chronic complications serves as a valuable tool. Further chapters summarize available therapies, their rationale, and indication. This includes various medical and surgical treatments with a review of dermatome shaving. Lastly, tattoo removal by gold standard YAG lasers and the more recent pico-second lasers is discussed with the optimal therapeutic outcome in mind.

Dermatologists, plastic surgeons, general practitioners, laser surgeons, and other specialists treating tattoo complications will find this book to be an indispensable resource. It also includes information relevant for a broad range of stakeholders in the tattoo business, including authorities and regulators.

Contents

Preface: **Serup, J.; Bäumlér, W.**

- From Technique of Tattooing to Biokinetics and Toxicology of Injected Tattoo Ink Particles and Chemicals: **Serup, J.**
- Individual Risk and Prevention of Complications: Doctors' Advice to Persons Wishing a New Tattoo: **Serup, J.**
- Tattoo Infections, Personal Resistance, and Contagious Exposure through Tattooing: **Serup, J.**
- Diagnostic Tools for Doctors' Evaluation of Tattoo Complications: **Serup, J.**
- How to Diagnose and Classify Tattoo Complications in the Clinic: A System of Distinctive Patterns: **Serup, J.**
- Medical Treatment of Tattoo Complications: **Serup, J.**
- Surgical Treatment of Tattoo Complications: **Sepehri, M.; Jørgensen, B.**
- Laser Treatment of Tattoos: Basic Principles: **Bäumlér, W.**
- Removal of Tattoos by Q-Switched Nanosecond Lasers: **Karsai, S.**
- New and Advanced Picosecond Lasers for Tattoo Removals: **Adatto, M.A.; Amir, R.; Bhawalkar, J.; Sierra, R.; Bankowski, R.; Rozen D.; Dierickx, C.; Lapidoth, M.**
- Laser Surgeon, Client Education, and Satisfaction with Tattoo Removal: **Hutton Carlsen, K.; Esmann, J.; Serup, J.**
- Guide to Treatment of Tattoo Complications and Tattoo Removal: **Serup, J.; Bäumlér, W.**
- Atlas of Illustrative Cases
- Index of Cases

Author Index/Subject Index

The easiest way to order: www.karger.com/cupde

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

KARGER

Bridging computer science and biomedicine

.... digital
BIOMARKERS

Submit
your paper
now!

Editor-in-Chief

E. R. Dorsey, Rochester, NY

Section Editor

"Network of Digital Evidence (NODE)"

A. Atreja, New York, NY

Advisory Board

M. Frasier, New York, NY

E. Hafen, Zurich

T. Heldt, Cambridge, MA

J.D. Hixson, San Francisco, CA

D. Karlin, Cambridge, MA

J. Kvedar, Boston, MA

M. Little, Birmingham

K.D. Mandl, Boston, MA

W.J. Marks Jr., San Francisco, CA

M. Rebhan, Basel

S. Scherer, East Hanover, NJ

T. Schwede, Basel

J. Wilbanks, Seattle, Wash.

www.karger.com/dib

- peer-reviewed
- fast online publication
- no article processing charge
- access to data, algorithms and app-repositories

Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables or ingestibles. The data collected is typically used to explain, influence and/or predict health-related outcomes. Digital biomarkers also represent an opportunity to capture clinically meaningful, objective data.

Multidisciplinary by design, this innovative open access journal bridges the disciplines of computer science, engineering, biomedicine, regulatory science and informatics. Papers are published within 60 days of submission and the inclusion of videos or other visual materials is supported. Moreover, *Digital Biomarkers* provides and supports access to data, algorithms and app-repositories linked to the articles published in the journal.

Digital Biomarkers

Founded: 2017

Category: Clinical Research

Fields of Interest: *Bioinformatics, Digital Medicine*



2018: Volume 2
Language: English
e-ISSN 2504-110X

More information at
www.digitalbiomarkers.info




An international forum on all aspects of
antimicrobial and antitumor chemotherapy

Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome



This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamic properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.

Chemotherapy

Founded: 1959

Category: Clinical and Basic Research

Fields of Interest: Infectious Diseases, Oncology

Listed in bibliographic services, including:

PubMed/MEDLINE, Web of Science,

Google Scholar, Scopus, Embase

2018: Volume 63

6 issues per volume

Language: English

ISSN 0009-3157

e-ISSN 1421-9794

Impact Factor: 0.843

Selected contributions

- Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report: **Ben Zvi M.** (Tel Aviv) **et al.**
- New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU-Therapy in Combination with Cisplatin: **Heinemann V.** (München) **et al.**
- Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer: **Frieling L.M.** (Maastricht/Eindhoven) **et al.**
- Potential of Casiopeinas® Copper Complexes and Antituberculosis Drug Combination against *Mycobacterium tuberculosis*: **Barbosa A.R.** (São Paulo) **et al.**
- Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma: **Kato H.** (Nagoya) **et al.**
- Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004–2014): **Rodloff A.C.** (Leipzig); **Dowzicky M.J.** (Collegeville, Pa.)
- Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells: **Kazama I.** (Sendai) **et al.**
- Characterization of Integrins and Sulfonamide Resistance Genes among Bacteria from Drinking Water Distribution Systems in Southwestern Nigeria: **Adesoji A.T.**; **Ogunjobi A.A.** (Ibadan); **Olatoye I.O.** (Ibadan/Pullman, Wash.)
- Do You Know Pixantrone?: **Minotti, G.**; **Menna, P.**; **Salvatorelli, E.** (Rome)
- Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview: **Menna, P.**; **Salvatorelli, E.** (Rome)

More information at www.karger.com/che

KARGER

Dermatology

(Continued from back cover)

Skin Cancer – Original Paper

404 Evaluation of the National Swiss Skin Cancer Screening Campaign 2013: Do We Do the Right Thing

Braun, R.-P.; Ulrich, K. (Zurich); Hunger, R. (Bern); Gaide, O. (Lausanne); Arnold, A. (Basel); Merat, R. (Geneva); Dummer, R.; Hafner, J.; French, L.E. (Zurich); Cozzio, A. (Zurich/St. Gallen)

The costs of free screening programs compare favorably with the prevented potential therapeutic costs of late-stage melanoma.

Letter to Dermatology

410 Melanoma Screening

Jørgensen, K.J. (Copenhagen)

Melanoma screening exists without evidence and should not be performed outside a randomised trial due to serious harms.

Dermatology

Review Papers

333 Emerging Treatment Options in Atopic Dermatitis: Topical Therapies

Nygaard, U.; Deleuran, M.; Vestergaard, C. (Aarhus)

In this review, we present emerging topical therapies in a systematic fashion by summarizing the major background information followed by an appraisal of the existing data and studies related to the drugs.

344 Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies

Nygaard, U.; Vestergaard, C.; Deleuran, M. (Aarhus)

We present emerging therapies in a systematic fashion by summarizing the major background information on each therapeutic target, directly followed by an appraisal of the existing data and studies involving the drugs in this category.

358 Skin Infections due to Bacteria in Solid Organ Transplant Recipients: A Review

Ilyas, M.; Maganty, N.; Ginsberg, Z.; Sharma, A. (Scottsdale, AZ)

A comprehensive review of bacterial cutaneous infections in the solid organ transplant population is presented.

IDEOM – Original Paper

366 Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

Naik, G.S. (Boston, MA); Ming, W.K. (Boston, MA/Guangzhou); Magodoro, I.M.; Akinwunmi, B.; Dar, S. (Boston, MA); Poulsen, H.E.; Kristensen, L.E. (Copenhagen); Ellervik, C. (Boston, MA/Copenhagen/Sorø)

In active psoriatic arthritis, Th17 inhibitors produce a clinically significant improvement in joint disease activity.

Original Paper

378 Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies

Kyriakou, A.; Patsatsi, A.; Sotiriadis, D.; Goulis D.G. (Thessaloniki)

Resistin concentrations are higher and adiponectin concentrations are lower in patients with psoriasis, supporting a pathogenic link between psoriasis and metabolic syndrome/obesity.

Clinical Investigations

390 Palmar Telangiectasias: A Cutaneous Sign for Smoking

Levi A. (Petah Tikva/Tel Aviv); Shechter, R. (Jerusalem); Lapidot, M. (Petah Tikva/Tel Aviv); Enk, C.D. (Jerusalem)

The presence of palmar telangiectasias is highly indicative of past or present smoking.

IDEOM – Original Paper

396 Low Utilization of the Dermatology Ambulatory Encounter among Patients with Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Analysis in the USA

Garg, A.; Lavian, J.; Strunk, A. (New Hyde Park, NY)

There is low ambulatory dermatology utilization among hidradenitis suppurativa patients in the USA.

Letters to Dermatology

399 The Magnitude of mTORC1 Signalling May Predict the Response to Isotretinoin Treatment in Patients with Hidradenitis Suppurativa

De Vita, (Naples); V.; Melnik, B.C. (Osnabrück)

HS patients who have higher levels of mTOR expression may represent an inflammation-prone subgroup who may exhibit a higher benefit from isotretinoin treatment.

401 Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid

Schaffer C.; Buclin, T.; Jornayvaz, F.R. (Lausanne); Cazzaniga, S. (Bern/Bergamo); Borradori, L. (Bern); Gilliet M. (Lausanne); Feldmeyer L. (Lausanne/Bern)

Our retrospective case-control study raises the awareness that BP might be a potential side effect of DPP4i.

(Continued on inside back cover)